Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study
Proactive TDM showed no significant differences in treatment outcomes compared to reactive TDM. However, the results in both the reactive and proactive TDM groups were not worse than those reported in other studies. Further studies with larger samples are needed to optimize the treatment strategies for pediatric IBD patients.
Authors
- Susana Clemente (ORCID: https://orcid.org/0000-0001-6272-6438)
- Núria Padullés Zamora (ORCID: https://orcid.org/0000-0002-8783-3042)
- Ana Vázquez (ORCID: https://orcid.org/0000-0001-6732-1667)
- M. J. Cabañas Poy (ORCID: https://orcid.org/0000-0003-2724-2715)
- Maria Teresa Sanz-Martínez (ORCID: https://orcid.org/0000-0001-5814-8698)
- María Queralt Gorgas (ORCID: https://orcid.org/0000-0001-5523-5171)
- María Larrosa-García (ORCID: https://orcid.org/0000-0001-6492-0568)
- Óscar Segarra Cantón
- Sonia García-García (ORCID: https://orcid.org/0000-0002-7505-4770)
- Marta Miarons (ORCID: https://orcid.org/0000-0001-7847-1580)
- Marina Álvarez Beltrán
Institutions
- Universitat Autònoma de Barcelona (ES)
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitari de Vic (ES)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2024-12-10
- DOI
- https://doi.org/10.3390/pharmaceutics16121577
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.55
Funders
- Universitat de Barcelona
- Universitat Autònoma de Barcelona
- Sociedad Española de Farmacia Hospitalaria